AnaptysBio, Inc.

AnaptysBio, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of novel antibody-based therapeutics for patients suffering from severe immune-mediated diseases. The company's pipeline is built upon a deep understanding of immunology, featuring several promising drug candidates designed to modulate key pathways involved in autoimmune and inflammatory conditions. Among its lead programs is Rosnilimab, an IgG1 antibody targeting PD-1+ T cells, which aims to broadly address pathogenic drivers of disease. Another significant asset is ANB032, a non-depleting antibody that inhibits activated T cell proliferation by binding to the BTLA checkpoint receptor. The company is also advancing ANB033, a novel antagonist antibody targeting the shared common beta subunit of IL-15 and IL-2 receptors, and ANB101, a BDCA2 modulator antibody specifically designed to target plasmacytoid dendritic cells. Furthermore, Imsidolimab, an antibody inhibiting the interleukin-36 receptor, is currently in Phase 3 development for generalized pustular psoriasis. AnaptysBio leverages strategic collaborations, including a significant agreement with GlaxoSmithKline, Inc., to advance its diverse antibody programs through preclinical and clinical milestones, aiming to establish a strong market position in the immunology therapeutics space by addressing unmet medical needs across a range of debilitating diseases.